The CDC is investigating cases of hospitalization due to cardiac or neurological events following vaccination with IXCHIQ, a chikungunya vaccine, among individuals aged 65 and older.

Clinical trials have shown that the vaccine produces a high seroresponse rate, but long-term immune response data is still being collected.

Common adverse reactions include tenderness, headache, fatigue, muscle pain, joint pain, fever, and nausea.

The vaccine is recommended for travelers to areas with chikungunya virus transmission. Health care providers are advised to assess the benefits and risks for each traveler.